



(11) **EP 1 579 872 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 72

(48) Corrigendum issued on:
07.11.2012 Bulletin 2012/45

(45) Date of publication and mention
of the grant of the patent:
28.03.2012 Bulletin 2012/13

(21) Application number: **03768195.4**

(22) Date of filing: **25.12.2003**

(51) Int Cl.:
A61K 31/4245 ^(2006.01) **A61K 31/4439** ^(2006.01)
A61K 45/00 ^(2006.01) **A61P 3/04** ^(2006.01)

(86) International application number:
PCT/JP2003/016656

(87) International publication number:
WO 2004/060399 (22.07.2004 Gazette 2004/30)

(54) **BODY WEIGHT GAIN INHIBITOR**

MITTEL ZUR HEMMUNG DER KÖRPERGEWICHTSZUNAHME
INHIBITEUR DE PRISE DE POIDS CORPOREL

(84) Designated Contracting States:
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IT LI LU MC NL PT RO SE SI SK TR**

(30) Priority: **27.12.2002 JP 2002380386**

(43) Date of publication of application:
28.09.2005 Bulletin 2005/39

(73) Proprietor: **Takeda Pharmaceutical Company
Limited
Osaka-shi,
Osaka 541-0045 (JP)**

(72) Inventors:
• **TERASHITA, Zen-ichi
Osaka-shi, Osaka 532-8686 (JP)**
• **KUSUMOTO, Keiji
Osaka-shi, Osaka 532-8686 (JP)**
• **YAMAGUCHI, Fuminari
Osaka-shi, Osaka 532-8686 (JP)**
• **IMURA, Yoshimi
Osaka-shi, Osaka 532-8686 (JP)**

(74) Representative: **König, Gregor Sebastian et al
König Szynka Tilmann von Renesse
Patentanwälte Partnerschaft
Postfach 11 09 46
40509 Düsseldorf (DE)**

(56) References cited:
**WO-A1-01/05428 WO-A1-01/60362
WO-A1-01/60410 WO-A1-02/15935
WO-A1-02/074340 WO-A1-03/013609
WO-A1-03/047573 WO-A2-01/76573
WO-A2-01/76574 WO-A2-02/15933
JP-A- 11 043 474**

- **ORTLEPP JAN R ET AL: "Angiotensin II receptor antagonism and ACE inhibition ameliorate hyperinsulinemia and obesity in a murine model of polygenic obesity" JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 39, no. 5 Supplement A, 6 March 2002 (2002-03-06), page 232A, XP002362571 & 51ST ANNUAL SCIENTIFIC SESSION OF THE AMERICAN COLLEGE OF CARDIOLOGY; ATLANTA, GA, USA; MARCH 17-20, 2002 ISSN: 0735-1097**
- **NODA M. ET AL: 'Involvement of angiotensin II in progression of renal injury in rats with genetic non-insulin-dependent diabetes mellitus (Wistar fatty rats)' JPN J. PHARMACOL. vol. 85, no. 4, 2001, pages 416 - 422, XP002977899**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 1 579 872 B8